Quick Answer
PROKIDNEY CORP. reported R&D Expense of $114.12 million for fiscal year 2025.
PROKIDNEY CORP. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $114.12M | -10.6% |
| 2024 | $127.67M | +19.6% |
| 2023 | $106.71M | +30.0% |
| 2022 | $82.07M | +77.4% |
| 2021 | $46.26M | +119.8% |
| 2020 | $21.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.82M | -14.2% | +3.6% |
| June 30, 2025 | $25.88M | -12.0% | -5.1% |
| March 31, 2025 | $27.26M | +0.1% | -12.8% |
| September 30, 2024 | $31.25M | -2.9% | +6.3% |
| June 30, 2024 | $29.40M | +11.5% | +8.0% |
| March 31, 2024 | $27.23M | +6.3% | -15.4% |
| September 30, 2023 | $32.20M | +52.4% | +22.1% |
| June 30, 2023 | $26.36M | +128.1% | +2.9% |
- PROKIDNEY CORP. showed a decrease of -10.6% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, PROKIDNEY CORP.’s r&d expense has grown by 442.4% (from $21.04 million to $114.12 million).
- The most recent figure is from PROKIDNEY CORP.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: